Our findings also identify that co-treatment of ziftomenib with BCL2, CDK6 or BET inhibitor induces synergistic in vitro lethality in AML cells with MLL1-r or mtNPM1. This evidence concerns the gene BCL2 and acute myeloid leukemia.